Skip to Main Content

What does the rest of 2018 have in store for biotech?

On Tuesday, we hosted a conference call with STAT Plus subscribers to briefly recap the year so far and chew over some of the major biotech events we’re looking out for in the coming months. That means discussing Celgene’s upcoming cancer data, Sarepta Therapeutics’ future in gene therapy, the gene-editing prospects for Sangamo Therapeutics, and the risks surrounding Esperion Therapeutics’ cholesterol drug. We also touched on Amarin, Global Blood Therapeutics, and the existential crisis facing large-cap biotech companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!